Laboratory and animal studies have shown that metformin may reduce vasoactive factors including VEGF, angiopoietins, cyclooxygenase-2 (COX-2) and nitric oxide synthase (NOS), potentially reducing the vascular alterations underlying the pathogenesis of OHSS (34, 35). This evidence concerns the gene PTGS2 and ovarian hyperstimulation syndrome.